Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
jueves, octubre 22
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Treace Medical Concepts Inc
TMCI
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$4.14
0.07
1.72%
Últ. Act.: Oct 19, 4:00 PM
$3.88
-0.19
-4.67%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
Privacy Manager
Treace Medical Concepts Financials
Treace Medical Concepts (TMCI) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Treace Medical Concepts Q2 EPS $(0.24) Beats $(0.30) Estimate, Sales $45.376M Beat $44.020M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.30) by 20 percent. This is a 14.29 percent increase over losses of $(0.28) per share
Benzinga Newsdesk
PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $202.000M-$212.000M to $204.000M-$212.000M vs $206.220M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $202.000 million-$212.000 million to $204.000 million-$212.000 million vs $206.220 million estimate.
Benzinga Newsdesk
PRO
Treace Medical Concepts Raises FY2026 Sales Guidance from $200.000M-$212.000M to $202.000M-$212.000M vs $205.920M Est
Treace Medical Concepts (NASDAQ:TMCI) raises FY2026 sales outlook from $200.000 million-$212.000 million to $202.000 million-$212.000 million vs $205.920 million estimate.
Benzinga Newsdesk
PRO
Treace Medical Concepts Q1 EPS $(0.28) Beats $(0.31) Estimate, Sales $47.198M Beat $45.960M Estimate
Treace Medical Concepts (NASDAQ:TMCI) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.31) by 9.68 percent. This is a 12 percent decrease over losses of $(0.25) per share
Benzinga Newsdesk
PRO
Treace Medical Concepts Sees FY2026 Sales $200.000M-$212.000M vs $210.335M Est
2026 Financial OutlookThe Company is initiating full-year 2026 revenue guidance of $200 million to $212 million representing a decline of 6% to 0% compared to full-year 2025.The Company expects a loss in Adjusted EBITDA
Benzinga Newsdesk
Treace Medical Concepts Q4 Earnings Summary & Key Takeaways
Benzinga Insights
